Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues-Reference-Cited by-同舟云学术

Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues

Published:2017-06-13 Issue:19 Volume:123 Page:3807-3815
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Majzner Robbie G.¹^ORCID,Simon Jason S.²,Grosso Joseph F.²,Martinez Daniel³⁴,Pawel Bruce R.³⁴,Santi Mariarita³⁴,Merchant Melinda S.⁵,Geoerger Birgit⁶,Hezam Imene⁶,Marty Virginie⁷,Vielh Phillippe⁷,Daugaard Mads⁸⁹,Sorensen Poul H.¹⁰,Mackall Crystal L.¹,Maris John M.¹¹⁴

Affiliation:

1. Department of Pediatrics; Stanford University; Stanford California

2. Bristol-Myers Squibb; Princeton New Jersey

3. Department of Pathology and Laboratory Medicine; Children's Hospital of Philadelphia; Philadelphia Pennsylvania

4. Perelman School of Medicine; University of Pennsylvania; Philadelphia Pennsylvania

5. Pediatric Oncology Branch, National Cancer Institute; Bethesda Maryland

6. Department of Pediatric and Adolescent Medicine; Gustave Roussy Institute; Villejuif France

7. Department of Medical Biology and Pathology; Gustave Roussy Institute; Villejuif France

8. Vancouver Prostate Center; Vancouver British Columbia Canada

9. Department of Urologic Sciences; University of British Columbia; Vancouver British Columbia Canada

10. British Columbia Cancer Agency; Vancouver British Columbia Canada

11. Department of Pediatrics; University of Pennsylvania; Philadelphia Pennsylvania

Funder

Bristol-Myers Squibb

Stand Up To Cancer

St. Baldrick's Foundation

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30724/fullpdf

Reference65 articles.

1. The journey from discoveries in fundamental immunology to cancer immunotherapy;Miller;Cancer Cell,2015

2. Bristol-Myers Squibb YERVOY [package insert] http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s00 00lbl.pdf 2016

3. Merck KEYTRUDA http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf 2016

4. Bristol-Myers Squibb OPDIVO http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125554lbl.pdf 2016

5. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer;Powles;Nature,2014

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies;Genes;2024-08-06

2. The administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature review;Pediatric pharmacology;2024-07-03

3. The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma;Cell Death & Disease;2024-06-18

4. Extracellular Vesicles from Highly Metastatic Osteosarcoma Cells Induce Pro‐Tumorigenic Macrophage Phenotypes;Advanced Biology;2024-04-10

5. Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma;2024-04-08